Effects of discontinuation of dasatinib or nilotinib in patients with chronic phase or accelerated phase chronic myeloid leukemia

Trial Profile

Effects of discontinuation of dasatinib or nilotinib in patients with chronic phase or accelerated phase chronic myeloid leukemia

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2016

At a glance

  • Drugs Dasatinib (Primary) ; Nilotinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms STOP 2G-TKI Study
  • Most Recent Events

    • 15 Dec 2016 New trial record
    • 08 Dec 2016 Results of interim analysis (n=60) published in the Blood
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top